Marksans Pharma Ltd announced on Monday that it has finalized an agreement to acquire 100% of the share capital of Netherlands-based QliniQ B.V., a move aimed at bolstering its presence in regulated European markets.
The Mumbai-based pharmaceutical firm indicated that this acquisition would enhance its strategy of forward integration by providing direct access to markets within the European Union.
QliniQ is recognized as a profitable pharmaceutical company with an established infrastructure for sales, marketing, and distribution within the Dutch healthcare market. The firm operates a diverse portfolio of niche pharmaceuticals and medical devices across specialty segments such as women’s health, dermatology, and respiratory care.
Albert de Bruin and Raymond Lansink, board members and shareholders of QliniQ B.V., expressed their enthusiasm about the acquisition, stating, “We are delighted that QliniQ is becoming part of the Marksans Group. During our discussions with Marksans, we were particularly impressed by the Company’s strong track record in product development, its clear long-term vision, and its commitment to quality and innovation.”
They further noted, “Marksans has built strong product development capabilities, a broad and growing portfolio, and high-quality manufacturing expertise. Combining these strengths with QliniQ’s market presence and local expertise creates a compelling opportunity for future growth and value creation.”
Mark Saldanha, Chairman and Managing Director of Marksans Pharma, emphasized that this acquisition would enable direct access to the Netherlands market and improve the company’s capacity to commercialize products across regulated European markets. “This acquisition represents an important strategic step in expanding Marksans’ presence across regulated European markets. QliniQ has built a profitable niche portfolio supported by established market access capabilities, long-standing customer relationships, and tender participation across the Netherlands healthcare ecosystem,” Saldanha stated.
He added, “The acquisition provides Marksans with direct access to the Netherlands market and enhances our ability to commercialize existing and future products across regulated European markets. We believe this will bolster our long-term growth opportunities and further enhance our global business.”
Marksans noted that the acquisition would grant it established sales, marketing, and distribution frameworks in the Netherlands, in addition to access to relationships with wholesalers, pharmacies, hospitals, and health insurers. This deal is also expected to strengthen Marksans’ role in insurer-led tender channels and provide access to EU GDP-compliant warehousing and regulatory infrastructure.
The company anticipates this acquisition will support the commercialization of both its existing and future product portfolio in the Netherlands, thereby reinforcing its long-term presence within regulated European markets.
Published on June 1, 2026
